SURGICAL CURES FOR DIABETES
|
|
- Robyn McCoy
- 6 years ago
- Views:
Transcription
1 SURGICAL CURES FOR DIABETES UCSF Diabetes Update March 12, 2009 Andrew M. Posselt, MD, PhD Transplant Surgery, UCSF
2 Surgical Treatment Options Whole Organ Pancreas Transplant Type 1 and 2 Pancreatic Islet Transplant Type 1 Bariatric Surgery Type 2
3 Pancreas Transplants Worldwide Number of Transplants pre 78 Total: n = 23,043 Non USA: n = 5,916 USA: n = 17, //05
4 Expansion of Selection Criteria Simultaneous pancreas-kidney transplant (SPK) Pancreas transplant after successful kidney transplant (PAK) Solitary pancreas transplant in the preuremic diabetic (PTA)
5 5-Year Pancreas/Kidney Graft Function USA DD Primary Pancreas Transplants, 1/1/ /31/ % PAK PTA SPK Px SPK Kd 1988/ / / / / / / / / /07 4/07
6 Pancreas Transplant for Type II DM Limited experience Works well in carefully selected pts. Combined with kidney transplant only Younger pts (< 45), BMI < 30 Insulin requirement usually not an issue
7 Effect on Secondary Complications Potential benefit is to halt the progression of complications of diabetes Patients present often with far advanced disease Difficult to demonstrate an impact on disease progression
8 Quality of Life More positive perception of health Less pain Greater ability to function socially Patients with failed grafts often return for retransplantation
9 Why transplant islets? Safer, simpler procedure than pancreas transplant Better control than insulin therapy
10 John D. Pirsch, Jon S. Odorico & Hans W. Sollinger
11
12 Pancreatic Islet Transplantation
13 Islet Processing GMP Facility
14 Islet Processing Head 62 grams Tail 15 grams
15 Fluoroscopy Islet Infusion Recovery
16 Edmonton Protocol - Steroid-free regimen - Short cold ischemia time - High quality islet preps - Immediate transplant - Usually 2 txps (>10,000 IE/kg) Shapiro AMJ et al., NEJM 2000;343:230-8
17 Graft Survival (Insulin Independence) Islet Transplant Registry Edmonton 87%
18 Insulin-independent islet allograft survival Edmonton/Miami/Minnesota (+ UCSF) n= yr insulin independence: 82 %
19 Insulin independence after 1:1 transplant % Insulin Independent Days Posttransplant
20 Glucose control after islet transplant Pre-transplant Post-transplant Blood Glucose (mg/dl) Blood Glucose (mg/dl) Fasting Before Lunch Before Dinner Bedtime 0 0 Fasting 1 Before 2 Lunch 3 4Before 5Dinner 6 Bedtime 7 8
21 Hypoglycemia Score HYPO Score Pre Tx 1 year post 2nd Tx Controls Ryan E et al., Diabetes 2004
22 The Vanishing Islet Allo ^ Ryan EA Diabetes 54: , 2005
23 5-year Graft Survival Rates in Islet and Pancreas Recipients Islet Pancreas % Insulin Independence Kaplan-Meier Estimates (n=20) 50% 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr 6 Yr Years Post Transplant % / / / / / / /01 PAK PTA SPK Px SPK Kd 50%! 2002/03
24 Decay in Islet Function Over Time Challenges and Opportunities Rejection? Autoimmunity? Inadequate site? Drug toxicity? No precursor cells? Biopsies Measurement of antibodies Different site? Different Immunosuppression?
25 New Immunosuppressive Agents LEA29Y (Belatacept) Efalizumab (Raptiva) Vincenti, AJT 2002
26 Graft Function with Raptiva Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Infusions 2/7/07 3/17/08 6/21/07 6/29/07 8/14/07 12/4/07 2/25/09 C Peptide at 1 mo Yes Yes Yes Yes Yes Insulin Independent >30d Yes Yes Yes Yes Yes Currently Insulin Independent Yes Yes Yes Yes +/- Duration of Independence > 5 mos (> 18 mos) > 14 mos > 14 mos > 12 mos 8 mos HbA1c Decr. > 2.5% Yes Yes Yes Yes Yes 2 patients treated with belatacept: both are insulin independent after single islet transplants
27 HbA1c after Islet Transplant 9 8 HbA1c (%) Pretxp 3 Months 6 Months 4 3 Pt 2 Pt 3 Pt 4
28 Metabolic Testing - MMTT Pt. 3 MMT Glucose 600 Glucose (mg/dl) Time (hrs) pretx d90 d180 Pt. 3 MMT C Peptide 10 C peptide (ng/ml) pretx d90 d Time (hrs)
29 Renal Function Serum Cr (mg/dl) PreTxp Time since Txp (d) Pt-1 Pt-2 Pt-3 Pt-4 Pt-5
30 Broad Indications for Beta Cell Replacement: Solid Organ Pancreas or Islets Pancreas (but not islets) Patients with large body habitus (>180lb) or large insulin requirements Patients with life-threatening diabetes and good cardiac reserve Patients receiving a simultaneous kidney with good cardiac reserve Islets (but not pancreas) Low BMI patients or patients with low insulin requirements who do not want invasive procedure Patients with life-threatening diabetes and high cardiac risks
31 The next steps New Agents New source Single donor Multicenter trials ? //
32 Ongoing Clinical Islet Transplant Trials at UCSF C Clinical i Clinical Islet Transplantation Consortium CIT 03 Islet alone +DSG CIT 07 Islet alone ctrl. CIT 06 Islet after kidney JDRF Trial: Islet Transplantation using a calcineurin-free immunosuppressive regimen based on Belatacept Other UCSF Trials: - IAK in HIV+ patients - SIK in diabetic children receiving live donor kidney txps
33 Diabetes in the United States, The number of Americans with diabetes increased from 5.6 to 15.8 million 24,000,000 w/ DM in 2007! 300,000,000 pop., 100,000,000 BMI>30
34 Obesity and Type II Diabetes Insulin resistance β-cell hypertrophy/hypermetabolism β-cell death Lean Obese Diabetic Insulin Glucagon, SS, PP Pick, Diabetes 47, 1998
35 Medical Therapies for Type 2 Diabetes Mellitus Usually address only glycemic control 30% effective in reducing HbA1c < 6%) Oral Agents: α-glucosidase inhibitors biguanides (metformin) meglitinides thiazolidinediones sulfonylureas Injectable Agents: Glucagon-like peptide-1 (GLP-1) analogues Exenatide (Byetta ) Liraglutide - longer t1/2; phase 3 trials Dipeptidyl peptidase-iv (DPP-IV) inhibitors Prevent breakdown of endogenous GLP- Sitagliptin (Januvia ) Vildagliptin (Galvus )
36 R-Y Gastric Bypass Gastric Banding BPD/DS 75% 22% 3% Sleeve Gastrectomy
37 Weight Loss Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects Sjöström et al. NEJM. 2007; 357 (8):741-52
38 Improvement/Resolution of Diabetes % Resolution/Improvement Diabetes % Band n=205 84% RYGBP n=989 98% BPD/DS n=288 P value <0.01 <0.01 NS vs. RYGBP, DS vs. Band vs. RYGBP Bariatric Surgery A Systematic Review and Meta-analysis. Buchwald H. et al. JAMA. 2004; 292(14):
39 Improvement/Resolution of Diabetes 35 DM II pre-op DM II 1 year FU 34% 34% 38% Imp./Resolved % Diabetic % Imp./Resolved P= % % Lap Gastric Bypass Lap Band Rabl C, Palazzo F, Rogers S, Posselt A, Cello J, Campos GM Laparoscopic Gastric Bypass is as Safe as Laparoscopic Gastric Banding and Provides Superior Weight Loss Outcomes. Obesity Surgery. 2008
40 Bariatric Surgery and T2DM Lap Band is superior to Non-Surgical Treatment Lap GBP is superior to Lap Banding BPD/DS effective but has significant SE s
41 Mechanisms for Diabetes Resolution after RYGBP - Calorie restriction and negative energy balance - Weight loss - Reduced carbohydrate intake (dumping) - Changes in adipocytokines - Altered synthesis of intestinal and pancreatic peptides that regulate glucose metabolism
42 GLUCOSE METABOLISM - INCRETINS GLP-1 (glucagon-like peptide-1) L cells in the distal portion of small bowel Promotes insulin production Suppresses glucagon secretion Reduces glucose production Decreases gastric emptying (satiety) GIP (Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide) K cells in duodenum and proximal small bowel Promotes insulin secretion In Type 2 DM: insulin secretory response to hyperglycemia is reduced In Euglycemia: stimulates Glucagon and does not No effect on gastric emptying
43 Glucose Levels During a Meal Test before and 2 weeks after Bypass or Calorie Restriction - Glucose excursions normalize sooner after RYGBP - No change in CR group Campos GM, Rabl C, Havel P, et al. NIH-NCRR Grant Number KL2 RR024130
44 Insulin Excursions During a Meal Test before and 2 weeks after Bypass or Calorie Restriction - Insulin secretion greater after RYGBP - No change in CR group Campos GM, Rabl C, Havel P, et al. NIH-NCRR Grant Number KL2 RR024130
45 GLP-1 Excursions During a Meal Test before and 2 weeks after Bypass or Calorie Restriction - GLP-1 secretion greater after RYGBP - No change in CR group Campos GM, Rabl C, Havel P, et al. NIH-NCRR Grant Number KL2 RR024130
46 GIP Excursions During a Meal Test before and 2 weeks after Bypass or Calorie Restriction - GIP secretion unchanged after RYGBP - GIP secretion increased in CR group Campos GM, Rabl C, Havel P, et al. NIH-NCRR Grant Number KL2 RR024130
47 Peripheral Glucose Uptake by Euglycemic Hyperinsulinemic Clamp after RYGBP P= mg/kg/min 6 4 P= Pre-op 15 days 6 months Campos GM, Rabl C, Havel P, et al. NIH-NCRR Grant Number KL2 RR024130
48 RYGBP, DM2 and Gut Hormones At 6 Months after RYGBP: - Altered pattern of gut (GLP-1, GIP) and pancreatic hormone (insulin, glucagon) secretion during meal - Improved peripheral glucose uptake, decreased fasting glucose GLP-1 GIP GLP-1 GIP Rubino, Ann Surg 236, 2002
49 Mechanisms for Weight loss and Diabetes Resolution after RYGBP or DS #1: Reduced Caloric Intake #2: Appetite + Ghrelin (stomach) + Insulin (pancreas) - Leptin (adipose tissue) - CCK (duodenum) Glucose Metabolism + Insulin (pancreas) - Glucagon (pancreas) + GLP-1 (distal small bowel) - GIP (proximal small bowel)
50 Islet Isolation Team: Courtney Cusack Pavel Koudria Jiena Lang Mike Lee Andrew Posselt Greg Szot Clinical Team: Lynda Frassetto Kristina Johnson Bob Kerlin Umesh Masharani Joan McElroy Debbie Ramos Tara Rojas Mehdi Tavakol Michael Worden Andrew Posselt Peter Stock Jeff Bluestone The GCRC Staff
Treating Type 2 Diabetes with Bariatric Surgery. Goal of Treating T2DM. Remission of T2DM with Bariatric
Treating Type 2 Diabetes with Bariatric Surgery Number (in Millions) of Persons with Diagnosed Diabetes, United States, 198 25 The number of Americans with diabetes increased from 5.6 to 15.8 million Guilherme
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationPathways to Protecting from Autoimmunity the Resurrected/Regenerated Beta Cells. Jeffrey Bluestone, PhD Diabetes Center at UCSF
Pathways to Protecting from Autoimmunity the Resurrected/Regenerated Beta Cells Jeffrey Bluestone, PhD Diabetes Center at UCSF Number of Transplants Is islet replacement a viable option? 2000 1800 1600
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationtype 2 diabetes is a surgical disease
M. Lannoo, MD, University Hospitals Leuven Walter Pories claimed in 1992 type 2 diabetes is a surgical disease Buchwald et al. conducted a large meta-analysis THE FIRST OBSERVATIONS W. Pories 500 patients
More informationEffect of macronutrients and mixed meals on incretin hormone secretion and islet cell function
Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function Background. Following meal ingestion, several hormones are released from the gastrointestinal tract. Some
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationGastric By-Pass and Remission of Type II Diabetes in Obese Adults
Cedarville University DigitalCommons@Cedarville Kinesiology and Allied Health Faculty Presentations Department of Kinesiology and Allied Health 2-6-2014 Gastric By-Pass and Remission of Type II Diabetes
More informationScope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors
Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationBARIATRIC SURGERY AND TYPE 2 DIABETES MELLITUS
BARIATRIC SURGERY AND TYPE 2 DIABETES MELLITUS George Vl Valsamakis European Scope Fellow Obesity Visiting iti Associate Prof Warwick Medical School Diabetes is an increasing healthcare epidemic throughout
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationRoux-and-Y Gastric Bypass and its Metabolic Effects
Roux-and-Y Gastric Bypass and its Metabolic Effects Nicola Di Lorenzo President elect of SICOb Italian Society for Bariatric Surgery and Metabolic Diseases Dept. of General Surgery-Università di Roma Tor
More informationβ-cell Preservation and Regeneration After Islet Transplantation
β-cell Preservation and Regeneration After Islet Transplantation Jyuhn-Huarng Juang, MD Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung University and Memorial Hospital,
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More information22 Emerging Therapies for
22 Emerging Therapies for Treatment of Type 2 Diabetes Siddharth N Shah Abstract: The prevalence of Diabetes is progressively increasing world-wide and the growth of the disease in our country is phenomenal.
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationEilandjes transplantatie. Eelco de Koning, LUMC 14 februari 2008
Eilandjes transplantatie Eelco de Koning, LUMC 14 februari 2008 Pancreas or islets? What tissue do we wish to transplant? Is there competition for donor pancreas? How does the islet isolation and transplantation
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationClinical Policy: Pancreas Transplantation Reference Number: PA.CP.MP.102
Clinical Policy: Reference Number: PA.CP.MP.102 Effective Date: 01/18 Last Review Date: 03/17 Revision Log Coding Implications Description This policy describes the medical necessity requirements for pancreas
More informationTechnique. Matthew Bettendorf, MD Essentia Health Duluth Clinic. Laparoscopic approach One 12mm port, Four 5mm ports
Matthew Bettendorf, MD Essentia Health Duluth Clinic Technique Laparoscopic approach One 12mm port, Four 5mm ports Single staple line with no anastamosis 85% gastrectomy Goal to remove
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationPancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry
American Journal of Transplantation 2016; 16: 688 693 Wiley Periodicals Inc. Brief Communication Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationMegan Lawless. Journal Club. January 20 th, 2011
Megan Lawless Journal Club January 20 th, 2011 Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1 Proceedings of the National Academy of Sciences September 2007 Abstract
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationDIABETES IN 2007 What snew
DIABETES IN 2007 What snew 1 Objectives 1. Review recently published clinical trials in diabetes What does this mean to us? 1. Discuss novel concepts in the treatment of diabetes What should we expect?
More informationEffect of Bariatric Surgery on Cardio-Metabolic Outcomes
Effect of Bariatric Surgery on Cardio-Metabolic Outcomes Disclosure Research support from Bariatric Advantage (supplements donated for research study) Anne Schafer, MD Associate Professor of Medicine and
More informationAbstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah
Effect of sitagliptin on glycemic control in patients with type 2 diabetes Abbas Mahdi Rahmah Correspondence: Dr. Abbas Mahdi Rahmah Consultant Endocrinologist, FRCP (Edin) Director of Iraqi National Diabetes
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationCurrent Trends in Bariatric Surgery
Current Trends in Bariatric Surgery 9.28.2017 Abraham Krikhely, MD, FACS, FASMBS Assistant Professor of Surgery, CUMC Center of Minimal Access, Metabolic and Weight Loss Surgery Outline Why consider surgery
More informationGastric Emptying Time after Laparoscopic Sleeve Gastrectomy
International Journal of Current Research in Medical Sciences ISSN: 2454-5716 P-ISJN: A4372-3064, E -ISJN: A4372-3061 www.ijcrims.com Original Research Article Volume 4, Issue 7-2018 Gastric Emptying Time
More informationBariatric Surgery For Patients With End-Organ Failure
Bariatric Surgery For Patients With End-Organ Failure Arnold D. Salzberg, M.D. Andrew M. Posselt, M.D., PhD Divisions of Transplant and Minimally Invasive Surgery University of California, San Francisco
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationCurrent Status of Bariatric Surgery in Asia
Emerald hall A, 1:2-1:5, November 7, 213 Current Status of Bariatric Surgery in Asia Go Wakabayashi, MD, PhD, FACS Professor and Chairman Department of Surgery Iwate Medical University Numbers of bariatric
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationNew Insights into Mechanism of Action
Remission of Diabetes after Bariatric Surgery New Insights into Mechanism of Action Peng (Charles) Zhang, MD, PhD Shanghai Pudong Hospital Fudan University Pudong Medical Center March 20, 2015 Orlando,
More informationNormal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),
Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), in which blood glucose predominantly originates from
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationFuture Therapies in the Treatment of Diabetes: Islet Transplantation
Future Therapies in the Treatment of Diabetes: Islet Transplantation Michael R. Rickels, MD, MS Associate Professor of Medicine University of Pennsylvania Perelman School of Medicine Medical Director,
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationWhat is Metabolic About Metabolic Surgery? The New ADA Recommendations
What is Metabolic About Metabolic Surgery? The New ADA Recommendations Obesity Symposium September 16, 2017 Timothy Howland, MD Lourdes Endocrinology Bariatric from the Greek root bar- ("weight" as in
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationUnderstanding the Effects of Roux-en-Y Gastric Bypass (RYGB) Surgery on Type 2 Diabetes Mellitus
Chapter 19 Understanding the Effects of Roux-en-Y Gastric Bypass (RYGB) Surgery on Type 2 Diabetes Mellitus Raymond G. Lau, Michael Radin, Collin E. Brathwaite and Louis Ragolia Additional information
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationKidney Transplantation
Kidney Tran nsplantation Historical per rspective and current practice Piyanut Poo otracool, M.D. Departmen nt of Surgery, Ramathibo odi Hospital, Mahidol University Kidney Transplantation DDKT Adult deceased
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationassociated with serious complications, but reduce occurrences with preventive measures
Wk 9. Management of Clients with Diabetes Mellitus 1. Diabetes Mellitus body s inability to metabolize carbohydrates, fats, proteins hyperglycemia associated with serious complications, but reduce occurrences
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationDIABETES UPDATE 2018
DIABETES UPDATE 2018 Jerome V. Tolbert, M.D., Ph.D. Assistant Professor of Medicine Icahn School of Medicine at Mt. Sinai Division of Endocrinology and Bone Diseases 317 East 17 th Street New York, New
More informationBariatric Procedures and Mechanisms of Weight Loss. September 22 nd, 2018 Aryan Modasi MD MSc FRCSC
Bariatric Procedures and Mechanisms of Weight Loss September 22 nd, 2018 Aryan Modasi MD MSc FRCSC Disclosures Nothing to Disclose Traditional View Restriction vs Malabsorption Traditional View Adjustable
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationMy Journey in Endocrinology. Samuel Cataland M.D
My Journey in Endocrinology Samuel Cataland M.D. 1968-2015 Drs Berson M.D. Yalow phd Insulin Radioimmunoassay Nobel Prize Physiology or Medicine 1977 Rosalyn Yalow: Radioimmunoassay Technology Andrew Schally
More informationType 2 diabetes and metabolic surgery:
Type 2 diabetes and metabolic surgery: Shouldn't we call it again again bariatric? Josep Vidal Obesity Unit. Endocrinology and Nutrition Department Hospital Clínic, University of Barcelona (Spain) What
More informationEAT TO LIVE: THE ROLE OF THE PANCREAS. Felicia V. Nowak, M.D., Ph.D. Ohio University COM 22 January, 2008
EAT TO LIVE: THE ROLE OF THE PANCREAS Felicia V. Nowak, M.D., Ph.D. Ohio University COM 22 January, 2008 THE ROLE OF THE PANCREAS Exocrine pancreas Endocrine pancreas THE ROLE OF THE PANCREAS EXOCRINE
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationPersonalized therapeutics in diabetes
Personalized therapeutics in diabetes Leen M. t Hart Molecular Cell Biology & Molecular Epidemiology Leiden University Medical Center Epidemiology & Biostatistics VU University Medical Center Diabetes
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationCorporate Medical Policy
Corporate Medical Policy Pancreas Transplant File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pancreas_transplant 1/2000 5/2017 5/2018 8/2017 Description of Procedure or Service Transplantation
More information(Incretin) ( glucagon-like peptide-1 GLP-1 ) GLP-1. GLP-1 ( dipeptidyl peptidase IV DPP IV ) GLP-1 DPP IV GLP-1 exenatide liraglutide FDA 2 2 2
007 18 189-194 (Incretin) Incretin ( ) -1 ( glucagon-like peptide-1 ) ( dipeptidyl peptidase IV ) liraglutide FDA ( Type diabetes mellitus ) -1 ( Glucagon-like peptide-1, ) ( Incretin ) ( Dipeptidyl peptidase
More informationResearch Article C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy
Diabetes Research Volume 2016, Article ID 4509603, 4 pages http://dx.doi.org/10.1155/2016/4509603 Research Article C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationManagement of Diabetes After Solid Organ Transplantation
Management of Diabetes After Solid Organ Transplantation Aidar R. Gosmanov, MD, PhD, FACE Chief, Endocrinology Section Stratton VAMC, Albany, NY Associate Professor of Medicine Division of Endocrinology,
More informationBariatric Surgery MM /11/2001. HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient; Inpatient
Bariatric Surgery Policy Number: Original Effective Date: MM.06.003 09/11/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient;
More informationINJECTABLE THERAPIES IN DIABETES. Barbara Ann McKee Diabetes Specialist Nurse
INJECTABLE THERAPIES IN DIABETES Barbara Ann McKee Diabetes Specialist Nurse 1 Aims of the session Describe the different injectable agents for diabetes and when they would be used. Describe some common
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationRestrictive Procedures: Band and Sleeve
Restrictive Procedures: Band and Sleeve Jin S. Yoo M.D. Assistant Professor of Surgery Jin.Yoo@duke.edu Disclosures Speaker for Cook Medical, Covidien, W.L. Gore Consultant for Musculoskeletal Transplant
More informationDiscussion & Conclusion
Discussion & Conclusion 7. Discussion DPP-4 inhibitors augment the effects of incretin hormones by prolonging their half-life and represent a new therapeutic approach for the treatment of type 2 diabetes
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More information